BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 30902704)

  • 21. Inhibitory effect of Phyllanthus urinaria L. extract on the replication of lamivudine-resistant hepatitis B virus in vitro.
    Jung J; Kim NK; Park S; Shin HJ; Hwang SG; Kim K
    BMC Complement Altern Med; 2015 Jul; 15():255. PubMed ID: 26220282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel method for nucleos(t)ide analogues susceptibility assay of hepatitis B virus by viral polymerase transcomplementation.
    Luo YY; Tao Y; Cai XF; Zhang WL; Long QX; Guo H; Huang AL; Hu JL
    Antiviral Res; 2016 Feb; 126():99-107. PubMed ID: 26738784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel fluoronucleoside analog NCC inhibits lamivudine-resistant hepatitis B virus in a hepatocyte model.
    Zhang J; Wang Y; Peng Y; Qin C; Liu Y; Li J; Jiang J; Zhou Y; Chang J; Wang Q
    Braz J Infect Dis; 2018; 22(6):477-486. PubMed ID: 30586543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
    van der Eijk AA; Hansen BE; Niesters HG; Janssen HL; van de Ende M; Schalm SW; de Man RA
    J Viral Hepat; 2005 Jul; 12(4):364-72. PubMed ID: 15985006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
    Chen RY; Edwards R; Shaw T; Colledge D; Delaney WE; Isom H; Bowden S; Desmond P; Locarnini SA
    Hepatology; 2003 Jan; 37(1):27-35. PubMed ID: 12500185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Determination of the lamivudine-resistant mutants of hepatitis B virus].
    Gervain J; Papp I; Csöndes M; Nemesánszky E; Rácz I; Ribiczey P; Telegdy L; Tornai I; Weisz G
    Orv Hetil; 2003 Jun; 144(25):1251-6. PubMed ID: 12901182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
    Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
    Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient.
    Zhang Q; Chen J; Pan M; Liu J; Liu T; Zhou YH
    Virus Res; 2018 Aug; 255():165-170. PubMed ID: 30075160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
    Amini-Bavil-Olyaee S; Herbers U; Mohebbi SR; Sabahi F; Zali MR; Luedde T; Trautwein C; Tacke F
    J Hepatol; 2009 Oct; 51(4):647-54. PubMed ID: 19586679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influences on viral replication and sensitivity to GLS4, a HAP compound, of naturally occurring T109/V124 mutations in hepatitis B virus core protein.
    Wang J; Zhang H; Zhang Y; Jiang D; Li J; Goldmann S; Ren Q; Fei R; Wang X; Wei L
    J Med Virol; 2017 Oct; 89(10):1804-1810. PubMed ID: 28401569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B.
    Coppola N; Tonziello G; Colombatto P; Pisaturo M; Messina V; Moriconi F; Alessio L; Sagnelli C; Cavallone D; Brunetto M; Sagnelli E
    J Infect; 2013 Oct; 67(4):322-8. PubMed ID: 23796869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Capsid Assembly Modulators Have a Dual Mechanism of Action in Primary Human Hepatocytes Infected with Hepatitis B Virus.
    Berke JM; Dehertogh P; Vergauwen K; Van Damme E; Mostmans W; Vandyck K; Pauwels F
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HBV carrying drug-resistance mutations in chronically infected treatment-naive patients.
    Gomes-Gouvêa MS; Ferreira AC; Teixeira R; Andrade JR; Ferreira AS; Barros LM; Rezende RE; Nastri AC; Leite AG; Piccoli LZ; Galvan J; Conde SR; Soares MC; Kliemann DA; Bertolini DA; Kunyoshi AS; Lyra AC; Oikawa MK; de Araújo LV; Carrilho FJ; Mendes-Corrêa MC; Pinho JR
    Antivir Ther; 2015; 20(4):387-95. PubMed ID: 25624410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.
    Mirandola S; Sebastiani G; Rossi C; Velo E; Erne EM; Vario A; Tempesta D; Romualdi C; Campagnolo D; Alberti A
    Antiviral Res; 2012 Dec; 96(3):422-9. PubMed ID: 23026293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance.
    Fu L; Cheng YC
    Biochem Pharmacol; 1998 May; 55(10):1567-72. PubMed ID: 9633992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation.
    Ji D; Liu Y; Li L; Xu Z; Si LL; Dai JZ; Li X; Wang L; Yao Z; Xin SJ; Chen GF; Xu D
    J Clin Virol; 2012 May; 54(1):66-72. PubMed ID: 22398037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy.
    Zhang Y; He S; Li QL; Guo JJ
    Virus Res; 2013 Nov; 177(2):156-62. PubMed ID: 23968804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the multifunctional HBV core protein as a potential cure for chronic hepatitis B.
    Viswanathan U; Mani N; Hu Z; Ban H; Du Y; Hu J; Chang J; Guo JT
    Antiviral Res; 2020 Oct; 182():104917. PubMed ID: 32818519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antisense oligodeoxynucleotides targeted against molecular chaperonin Hsp60 block human hepatitis B virus replication.
    Park SG; Lee SM; Jung G
    J Biol Chem; 2003 Oct; 278(41):39851-7. PubMed ID: 12869561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis B virus X gene mutants emerge during antiviral therapy and increase cccDNA levels to compensate for replication suppression.
    Lin CL; Chien RN; Chu YD; Liang KH; Huang YH; Ke PY; Lin KH; Lin YH; Yeh CT
    Hepatol Int; 2020 Dec; 14(6):973-984. PubMed ID: 32770306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.